Evaluation of the effect of highly effective multiple sclerosis disease-modifying drugs on the progression of the disease using diffusion-weighted magnetic resonance imaging with tractography

The comparison of the examination results of group 1 patients with those in the control group showed a decrease in the length of the pyramidal tract. However, there was no difference between the values before and after treatment. These results suggest that cladribine therapy contributes to slowing down neurodegenerative processes. Analysis of the results one year after the start of treatment with ocrelizumab showed a slight negative trend, indicating the progression of neurodegenerative processes. The observed results are probably due to more severe baseline impairment of the pyramidal function and ambulation in this group of patients compared to group 1.